GlassScriptPhysician profile
Jonnathan Rodriguez
NPI 1811410541
$2,030.15
in general payments reported to CMS, 2019-2025
21 companies · $1,229 in 2025
The $1,229 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28.61 · 2022: $33.87 · 2023: $18.91 · 2024: $720 · 2025: $1,229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,968.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,967.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $293.28 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $268.55 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $267.18 | 2024-2025 | |
| Abbvie INC. | $218.12 | 2024-2025 | |
| Lilly USA, LLC | $153.30 | 2024-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $121.78 | 2024-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $116.66 | 2024-2025 | Evenity, Otezla, Repatha |
| Dexcom, INC. | $90.18 | 2023-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $88.29 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.78 | 2024-2025 | Jardiance, Synjardy, Tradjenta |
| Exact Sciences Corporation | $63.45 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $55.37 | 2024-2025 | Gemtesa |
| Abbott Laboratories | $40.42 | 2025 | Freestyle Libre 3 |
| Masimo Corporation | $33.87 | 2022 | |
| Medtronic, INC. | $23.91 | 2025 | Inceptiv |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.94 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $21.26 | 2025 | |
| Antares Pharma, INC. | $20.53 | 2024 | Xyosted |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.73 | 2024 | Xifaxan |
| Kerecis Limited | $14.66 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| E.R. Squibb & Sons, L.L.C. | $13.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonnathan Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.